ZUMA-8 Trial: Advancing CAR T-Cell Therapy with Brexucabtagene Autoleucel in Relapsed/Refractory Chronic Lymphocytic Leukemia
Highlight
– ZUMA-8 is a phase 1 clinical trial evaluating brexucabtagene autoleucel (brexu-cel), a CD19-directed CAR T-cell therapy, in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL).
– Among 15 heavily pretreated patients, the overall response rate was 47%, with complete responses in 7%, notably higher responses observed in patients with low tumor burden.
– Safety signals were consistent with known CAR T-cell toxicities, including cytokine release syndrome and neurologic events, with one dose-limiting toxicity observed.
– CAR T-cell expansion correlated inversely with pre-leukapheresis lymphocyte counts, suggesting tumor burden may influence therapeutic kinetics.
Study Background and Disease Burden
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.